284 related articles for article (PubMed ID: 18991471)
1. Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients : a randomized, double-blind, placebo-controlled study.
Gursoy O; Memiş D; Sut N
Clin Drug Investig; 2008; 28(12):777-82. PubMed ID: 18991471
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
3. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
4. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
5. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Kromer W
Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
[TBL] [Abstract][Full Text] [Related]
6. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective disposition of proton pump inhibitors.
Andersson T; Weidolf L
Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
[TBL] [Abstract][Full Text] [Related]
8. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
[TBL] [Abstract][Full Text] [Related]
10. A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery.
Nishina K; Mikawa K; Takao Y; Shiga M; Maekawa N; Obara H
Anesth Analg; 2000 Mar; 90(3):717-21. PubMed ID: 10702463
[TBL] [Abstract][Full Text] [Related]
11. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
Pantoflickova D; Dorta G; Ravic M; Jornod P; Blum AL
Aliment Pharmacol Ther; 2003 Jun; 17(12):1507-14. PubMed ID: 12823153
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
13. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
Williams MP; Sercombe J; Hamilton MI; Pounder RE
Aliment Pharmacol Ther; 1998 Nov; 12(11):1079-89. PubMed ID: 9845397
[TBL] [Abstract][Full Text] [Related]
15. A glass of water immediately increases gastric pH in healthy subjects.
Karamanolis G; Theofanidou I; Yiasemidou M; Giannoulis E; Triantafyllou K; Ladas SD
Dig Dis Sci; 2008 Dec; 53(12):3128-32. PubMed ID: 18473176
[TBL] [Abstract][Full Text] [Related]
16. Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.
Akter S; Hassan MR; Shahriar M; Akter N; Abbas MG; Bhuiyan MA
Alzheimers Res Ther; 2015 Dec; 7():79. PubMed ID: 26714488
[TBL] [Abstract][Full Text] [Related]
17. Effects of ranitidine, famotidine, pantoprazole, and omeprazole on intragastric pH in dogs.
Bersenas AM; Mathews KA; Allen DG; Conlon PD
Am J Vet Res; 2005 Mar; 66(3):425-31. PubMed ID: 15822586
[TBL] [Abstract][Full Text] [Related]
18. Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole.
Belhocine K; Vavasseur F; Volteau C; Flet L; Touchefeu Y; Bruley des Varannes S
BMC Gastroenterol; 2014 Jul; 14():128. PubMed ID: 25027286
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.
Pratha VS; Hogan DL; Lane JR; Williams PJ; Burton MS; Lynn RB; Karlstadt RG
Dig Dis Sci; 2006 Jan; 51(1):123-31. PubMed ID: 16416224
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
